Drug Prescribing Practices for Tuberculosis in Uzbekistan
Results of Operational Research
Tashkent, 2008

Epco Hasker*, Maksad Khodjikhanov, Shahnaz Umarova, Umida Asamidinov, Umida Yuldasheva, Marieke J. van der Velden, Gulnora Uzakova, Jaap Veen

1. Project HOPE, Tuberculosis Control Program for the Central Asia Region
2. Department of Infectious Diseases, Tropical Medicine & AIDS, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, The Netherlands
3. Project Implementation Unit GPAIM, Uzbekistan
4. Epidemiology and Disease Control Unit, Department of Public Health Institute of Tropical Medicine Antwerp, Belgium
*Corresponding author

BACKGROUND

- Project HOPE has been working in Uzbekistan since 2000
- In 2005 Project HOPE with JSI assessed Drug management practices of TB program in Uzbekistan
- Recommendation: conduct survey on RDU in Uzbekistan

Uzbekistan

Study Questions:

- How many new TB patients are on correct (DOTS) treatment regimen?
- Additional TB drugs prescribed?
- Correct dosages?
- How many patients receive additional non-TB drugs?
- Which drugs?
- How many?
- What are the costs?
- Was treatment administered under DOT?

Gender characteristic of the study population

Social characteristics of the study population

Type of treatment

Treatment regimens prescribed by classification of patient

Pathology New Smear Positive

Pathology New Smear Negative

Treatment regimens prescribed by classification of patient

(225 Patients)

Prescribed dosages of 1st line anti-TB drugs

Top 10 of most frequently prescribed non-TB drugs

Cost of TB treatment

Patients that finished treatment, n=42

Financial problems

Number of interviewed patients, n=146

Do you ever get your TB drugs to take home with you?

Patients that started continuation phase, n=121

Conclusion

- Rx Regimens prescribed are adequate
- Choice of drugs adequate
- Dosages adequate
- Doubts about DOT
- Alternative Rx delivery options?
- Problem of additional non-TB drugs
- High costs for patients
- Potential adverse effects
- Evidence base?
- Limitations: Only New cases were assessed

Our plans

- Results of Operational research will present on TWG meeting
- National TB program will decide how to improve the situation of TB drugs use